Latest News
Category: News
News,
Cancer is a complex disease. Its growth is influenced not only by the cancer cells themselves but by its surroundings, known as the tumour microenvironment (TME). Telix is exploring a theranostic approach focused on this part of the tumour by targeting fibroblast activation protein or FAP, a cell-surface protein present on stroma cells in virtually all solid tumour types. This...
Read more
Telix announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol...
Read more
Telix today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce...
Read more
Telix today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals for Medicare Fee for...
Read more
News,
Telix today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix’s commercial PSMA-PET product, Illuccix®...
Read more
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®), an agent for the imaging of glioma....
Read more
Telix today announces the spin-off of Rhine Pharma, which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m(99mTc) and...
Read more
Telix announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of...
Read more
Telix today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3...
Read more
Telix today announces thirteen abstract presentations featuring the Company’s ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37th Annual Congress of the European Association...
Read more